Retatrutide appears to be a new pharmaceutical in the fight against obesity. This revolutionary drug, belonging to a dual GLP-1 and GIP receptor agonist, exhibits promising results in investigations. By activating these receptors, Retatrutide suppresses appetite, {promotesenergy expenditure, and ultimately contributes to significant reduction in bo